nach oben

Erschienen in:

01.04.2010 | Aktuelles

Kardiologische Diagnostik nach zerebraler Ischämie

Konsensuspapier der Arbeitsgemeinschaft Herz und Hirn der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK) und der Deutschen Schlaganfallgesellschaft e.V. (DSG)

verfasst von: Prof. Dr. U. Laufs, U.C. Hoppe, S. Rosenkranz, P. Kirchhof, M. Böhm, H.-C. Diener, M. Endres, M. Grond, W. Hacke, T. Meinertz, E.B. Ringelstein, J. Röther, M. Dichgans

Erschienen in: Der Nervenarzt | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Auszug

Dieses Konsensuspapier ist eine Stellungnahme der Arbeitsgemeinschaft Herz und Hirn der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK) und der Deutschen Schlaganfallgesellschaft e.V. (DSG), die den gegenwärtigen Kenntnisstand wiedergibt und in der Schlaganfallversorgung tätigen Ärzten die Entscheidungsfindung bei der Indikationsstellung zur kardiologischen Diagnostik und Labordiagnostik erleichtern soll. Es werden Empfehlungen zu den Indikationsbereichen für gängige diagnostische Verfahren und Tests gegeben. Auf die Kennzeichnung des Evidenzgrads wird verzichtet, da in der Regel keine spezifischen randomisierten Studien existieren und es sich überwiegend um die Konsensusmeinung von Experten basierend auf kleinen Fallserien und klinischer Erfahrung handelt. …

Diener HC, Putzki N et al (2008) Leitlinien der DGN 2008. In: Kommission „Leitlinien der Deutschen Gesellschaft für Neurologie“ (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie

The Europeen Stroke Organization (ESO) Executive Committe and the ESO Writing Committee (2008) Guidelines for managment of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507

Capes SE, Hunt D, Malmberg K et al (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426–2432PubMed

Alvarez-Sabin J, Molina CA, Montaner J et al (2003) Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator–treated patients. Stroke 34:1235–1241PubMed

McCormick MT, Muir KW, Gray CS et al (2008) Management of hyperglycemia in acute stroke: how, when, and for whom? Stroke 39:2177–2185PubMed

Fuentes B, Castillo J, San JB et al (2009) The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) Study. Stroke 40:562–568PubMed

Ringleb PA et al (2009) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. http://www.eso-stroke.org/pdf/ESO%20Guidelines_update_Jan_2009.pdf

Gray CS, Hildreth AJ, Sandercock PA et al (2007) Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397–406PubMed

Yong M, Kaste M (2008) Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 39:2749–2755PubMed

10.

Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J [Suppl 9]:C3–C74

11.

Kerner W, Brückel J (2007) Definition, Klassifikation und Diagnostik. Diabetologie [Suppl 2]:147–149

12.

Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829–1839

13.

Kurth T, Everett BM, Buring JE et al (2007) Lipid levels and the risk of ischemic stroke in women. Neurology 68:556–562PubMed

14.

Sanossian N, Tarlov NE (2008) HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment. Curr Treat Options Cardiovasc Med 10:195–206PubMed

15.

Bansal S, Buring JE, Rifai N et al (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316PubMed

16.

Freiberg JJ, Tybjaerg-Hansen A, Jensen JS et al (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300:2142–2152PubMed

17.

Bang OY, Saver JL, Liebeskind DS et al (2008) Association of serum lipid indices with large artery atherosclerotic stroke. Neurology 70:841–847PubMed

18.

Kamstrup PR, Tybjærg-Hansen A, Steffensen R et al (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331–2339PubMed

19.

Amarenco P, Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453–463PubMed

20.

Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360:7–22

21.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559

22.

Adams HP, Zoppo G del, Alberts MJ et al (2007) Atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups. Stroke 38:1655–1711PubMed

23.

Sacco RL, Adams R, Albers G et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113:409–449

24.

Pezzini A, Del ZE, Magoni M et al (2003) Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 34:28–33PubMed

25.

Botto N, Spadoni I, Giusti S et al (2007) Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 38:2070–2073PubMed

26.

Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 [Suppl 3]:401–428

27.

Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295:1050–1057PubMed

28.

Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022

29.

Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565–575PubMed

30.

Bonaa KH, Njolstad I, Ueland PM et al (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578–1588PubMed

31.

Lonn E, Yusuf S, Arnold MJ et al (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577PubMed

32.

Liman T, Endres M (2008) Elevated troponin and ECG alterations in acute ischemic stroke and subarachnoid hemorrhage. Nervenarzt 79:1386–1398PubMed

33.

Jensen JK, Kristensen SR, Bak S et al (2007) Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol 99108–99112

34.

James P, Ellis CJ, Whitlock RM et al (2000) Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ 320:1502–1504PubMed

35.

Di AE, Fiorelli M, Toni D et al (2005) Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 76:76–81

36.

Rubattu S, Sciarretta S, Valenti V et al (2008) Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21:733–741PubMed

37.

Kistorp C, Raymond I, Pedersen F et al (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616PubMed

38.

Di NM, Schwaninger M, Cappelli R et al (2005) Evaluation of C-reactive protein measurecument for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36:1316–1329

39.

Elkind MS (2009) Inflammatory markers and stroke. Curr Cardiol Rep 11:12–20PubMed

40.

Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMed

41.

Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115–126PubMed

42.

Ridker PM, Buring JE, Rifai N et al (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMed

43.

Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28PubMed

44.

Grau AJ, Weimar C, Buggle F et al (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32:559–566

45.

Dimant J, Grob D (1977) Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. Stroke 8:448–455PubMed

46.

Oppenheimer SA (1994) Neurogenic cardiac effects of cerebrovascular disease. Curr Opin Neurol 7:20–24PubMed

47.

Oppenheimer SM, Hachinski VC (1992) The cardiac consequences of stroke. Neurol Clin 10:167–176PubMed

48.

Mikolich JR, Jacobs WC, Fletcher GF (1981) Cardiac arrhythmias in patients with acute cerebrovascular accidents. JAMA 246:1314–1317PubMed

49.

Norris JF, Froggatt GM, Hachinski VC (1978) Cardiac arrhythmias in acute stroke. Stroke 9:392–396PubMed

50.

Hohnloser SH, Pajitnev D, Pogue J et al (2007) Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 50:2156–2161PubMed

51.

Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27:1979–2030PubMed

52.

Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867PubMed

53.

Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817PubMed

54.

Fetsch T, Bauer P, Engberding D et al (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385–1394PubMed

55.

Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224–227PubMed

56.

Brignole M, Vardas P, Hoffman E et al (2009) Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 11:671–687PubMed

57.

Barthelemy JC, Feasson-Gerard S, Garnier P et al (2003) Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol 8:194–199PubMed

58.

Hornig CR, Haberbosch W, Lammers C et al (1996) Specific cardiological evaluation after focal cerebral ischemia. Acta Neurol Scand 93:297–302PubMedCrossRef

59.

Jabaudon D, Sztajzel J, Sievert K et al (2004) Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 35:1647–1651PubMed

60.

Liao J, Khalid Z, Scallan C et al (2007) Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38:2935–2944PubMed

61.

Rem JA, Hachinski VC, Boughner DR et al (1985) Value of cardiac monitoring and echocardiography in TIA and stroke patients. Stroke 16:950–956PubMed

62.

Schaer BA, Zellweger MJ, Cron TA et al (2004) Value of routine holter monitoring for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemic events. Stroke 35:68–70

63.

Schuchert A, Behrens G, Meinertz T (1999) Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke. Pacing Clin Electrophysiol 22:1082–1084PubMed

64.

Shafqat S, Kelly PJ, Furie KL (2004) Holter monitoring in the diagnosis of stroke mechanism. Intern Med J 34:305–309PubMed

65.

Tayal AH, Tian M, Kelly KM et al (2008) Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 71:1696–1701PubMed

66.

Tagawa M, Takeuchi S, Chinushi M et al (2007) Evaluating patients with acute ischemic stroke with special reference to newly developed atrial fibrillation in cerebral embolism. Pacing Clin Electrophysiol 30:1121–1128PubMed

67.

Mant J, Hobbs FD, Fletcher K et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA) a randomised controlled trial. Lancet 370:493–503PubMed

68.

Knecht S, Oelschlager C, Duning T et al (2008) Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 29:2125–2132

69.

Miller VT, Pearce LA, Feinberg WM et al (1996) Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 46:238–240PubMed

70.

Marini C, De Santis F, Sacco S et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36:1115–1119PubMed

71.

Hoppe UC, Casares JM, Eiskjaer H et al (2006) Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114:18–25PubMed

72.

Israel CW, Gronefeld G, Ehrlich JR et al (2004) Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 43:47–52PubMed

73.

Capucci A, Santini M, Padeletti L et al (2005) Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 46:1913–1920PubMed

74.

Glotzer TV (2008) The TRENDS Study: Is there a critical value of daily atrial tachyarrhytmia burden from device diagnostics that raises stroke risk? ACC (Abstr)

75.

Glotzer TV, Hellkamp AS, Zimmerman J et al (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST) Circulation 107:1614–1619

76.

Petty GW, Brown RD Jr, Whisnant JP et al (1999) Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30:2513–2516PubMed

77.

Amarenco P, Röther J, Michel P et al (2006) Aortic arch atheroma and the risk of stroke. Curr Atheroscler Rep 8:343–346PubMed

78.

Agmon Y, Khandheria BK, Gentile F et al (2002) Clinical and echocardiographic characteristics of patients with left atrial thrombus and sinus rhythm: experience in 20.643 consecutive transesophageal echocardiographic examinations. Circulation 105:27–31PubMed

79.

Busse O, Darius H (2002) Indikationen zur Echokardiographie beim ischämischen zerebralen Insult. Nervenarzt 73:792–795PubMed

80.

Flemming KD, Brown RD Jr, Petty GW et al (2004) Evaluation and management of transient ischemic attack and minor cerebral infarction. Mayo Clin Proc 79:1071–1086PubMed

81.

Handke M, Harloff A, Olschewski M et al (2007) Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 357:2262–2268PubMed

82.

Overell JR, Bone I, Less KR (2000) Interatrial septal abnormalities and stroke. A meta-analysis of case-control studies. Neurology 55:1172–1179PubMed

83.

Meissner I, Whisnant JP, Khandheria BK et al (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc 74:862–869PubMed

84.

Mas JL, Arquizan C, Lamy C et al (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345:1740–1746PubMed

85.

Giardini A, Donti A, Formigari R et al (2004) Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol 94:1012–1016PubMed

86.

Goel SS, Tuzcu EM, Shishehbor MH et al (2009) Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol 103:124–129PubMed

87.

Homma S, Sacco RL, Di Tullio MR et al (2002) Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 105:2625–2631PubMed

88.

Messe S, Silverman I, Kizer J et al (2004) Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 62:1042–1050PubMed

89.

Slottow TL, Steinberg DH, Waksman R (2007) Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation 116:677–682PubMed

90.

Hung J, Landzberg MJ, Jenkins KJ et al (2000) Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 35:1311–1316PubMed

91.

Khairy P, O’Donnell CP, Landzberg MJ (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 139:753–760PubMed

92.

Braun MU, Fassbender D, Schoen SP et al (2002) Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 39:2019–2025PubMed

93.

Windecker S, Wahl A, Chatterjee T et al (2000) Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 101:893–898PubMed

94.

Cifarelli A, Musto C, Parma A et al (2009) Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism. Int J Cardiol (Epub ahead of print)

95.

Rigatelli G, Aggio S, Cardaioli P et al (2009) Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism? JACC Cardiovasc Interv 2:655–662PubMed

96.

Berthet K, Lavergne T, Cohen A et al (2000) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31(2):398–403PubMed

97.

Wöhrle J, Kochs M, Spiess et al (2009) Impact of percutaneous device implantation for closure of patent foramen ovale on valve insufficiencies. Circulation 119:3002–3008PubMed

98.

Chiarella F, Santoro E, Domenicucci S et al (1998) Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. Am J Cardiol 81:822–827PubMed

99.

Anzola G, Morandi E, Casilli F et al (2004) Does transcatheter closure of patent foramen ovale really „ shut the door?“ – A prospective study with transcranial doppler. Stroke 35:2140–2144PubMed

100.

Serena J, Marti-Fàbregas J, Santamarina E et al (2008) Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 39:3131–3139PubMed

101.

Torti SR, Billinger M, Schwerzmann M et al (2004) Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 25:2173–2174

102.

Tunick PA, Nayar AC, Goodkin GM et al (2002) NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90:1320–1325PubMed

103.

Cheitlin MD, Armstrong WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 42:954–970PubMed

104.

Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489–496PubMed

105.

Pullicino PM, Halperin JL, Thompson JLP (2000) Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 54:288–294PubMed

106.

Massie BM, Collins JF, Ammon SE et al (2009) WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119:1616–1624PubMed

107.

Krinsky G, Maya M, Rofsky N et al (1998) Gadolinium-enhanced 3D MRA of the aortic arch vessels in the detection of atherosclerotic cerebrovascular occlusive disease. J Comput Assist Tomogr 22:167–178PubMed

108.

Ferrari E, Vidal R, Chevallier T et al (1999) Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: Benefit of oral anticoagulants. J Am Coll Cardiol 33:1317–1322PubMed

109.

Ringelstein EB, Arnold M, Dittrich R et al (2008) Dissektionen hirnversorgender supraaortaler Arterien, in: Kommission „Leitlinien der Deutschen Gesellschaft für Neurologie“ (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie 288–297

110.

Amarenco P, Cohen A, Tzourio C et al (1994) Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331:1474–1479PubMed

111.

Harloff A, Strecker C, Dudler P et al (2009) Retrograde embolism from the descending aorta: visualization by multidirectional 3D velocity mapping in cryptogenic stroke. Stroke 40:1505–1508PubMed

112.

Mohr JP, Thompson JL, Lazar RM et al (2001) Warfarin-Aspirin Recurrent Stroke Study Group (WARSS). A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444–1451PubMed

113.

Tunick PA, Nayar AC, Goodkin GM et al (2002) Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90:1320PubMed

114.

Cannegieter S, Rosendaal F, Wintzen A et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17PubMed

115.

Salem DN, Levine HJ, Pauker SG et al (1998) Antithrombotic therapy in valvular heart disease. Chest 114 [Suppl]:590–601

116.

Bonow RO, Carabello BA, Chatterjee K et al (2008) Focused Update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. a report of the american college of cardiology/american heart association task force on practice guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation 118:523–661

117.

Gilon D, Bounanno FS, Joffe MM et al (1999) Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med 341:8–13PubMed

118.

Baddour LM, Wilson WR, Bayer AS et al (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:394–434

119.

Cartoni D, De Castro S, Valente G et al (2004) Identification of professional scuba divers with patent foramen ovale at risk for decompression illness. Am J Cardiol 94:270–273PubMed

120.

Weimar C, Holle DN, Benemann J (2009) German Stroke Study Collaboration. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis 28:349–356PubMed

121.

Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J [Epub ahead of print] PMID: 19713419

122.

Kapral MK, Silver FL (1999) Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. CMAJ 161:989–996PubMed

123.

Peterson GE, Brickner ME, Reimold SC (2003) Transesophageal echocardiography: Clinical indications and applications. Circulation 107:2398–2402PubMed

124.

Lerakis S, Nicholson WJ (2005) Part I. Use of echocardiography in the evaluation of patients with suspected cardioembolic stroke. Am J Med Sci 329:310–316PubMed

125.

Zabalgoitia M, Halperin JL, Pearce LA et al (1998) Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 31:1622–1626PubMed

126.

Hankey GJ, Jamrozik K, Broadhurst RJ et al (2000) Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 31:2080–2086PubMed

127.

O’Rourke RA, Brundage BH, Froelicher VF et al (2000) American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease. Circulation 102:126–140

128.

Michaelides AP, Psomadaki ZD, Dilaveris PE et al (1999) Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads. N Engl J Med 340:340–345PubMed

129.

Baer FM (2007) Stress-ECG is the first step to assess myocardial ischemia: when are additional diagnostic tests needed? Dtsch Med Wochenschr 132:2026–2030PubMed

130.

Evans A, Perez I, Yu G et al (2001) Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 32:2828–2832PubMed

131.

132.

Bethesda M (1993) National cholesterol education program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Nat Heart Lung Blood Inst, pp 93–3095

133.

Law M, Wald N, Rudnicka A (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423PubMed

134.

Cholesterol Treatment Trialists (CTT) Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371:117–125

135.

Patten, M, Maas R, Bauer P et al (2004) Suppression of paroxysmal atrial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 25:1395–1404PubMed

136.

Botto G, Padeletti L, Santini M et al (2009) Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 20:241–248PubMed

137.

Barkan D, Abu Fanne R, Elazari-Scheiman A et al (2007) Navel piercing as a cause for Streptococcus viridans endocarditis: case report, review of the literature and implications for antibiotic prophylaxis. Cardiology 108:159–160PubMed

138.

Bogousslavsky J, Regli F (1987) Ischemic stroke in adults younger than 30 years of age: cause and prognosis. Arch Neurol 44:4779–4782

139.

De Bruijn SF, Agema WR, Lammers GJ et al (2006) Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke 37:2531–2534

140.

Di Tulio MR, Homma S (2002) Mechanisms of cardioembolic stroke. Curr Cardiol Rep 4:141–148

141.

Hardman SMC, Cowie MR (1999) Anticoagulation in heart disease. Br Med J 318:238–244

142.

Meyer R (2001) Piercing: Gefährlicher Körperschmuck. Dtsch Ärztebl 98:A819–A820

143.

Stroke Prevention in Atrial Fibrillation Study Group (1992) Predictors of thromboembolism in atrial fibrillation. Echocardiographic features of patients at risk. Ann Intern Med 116:6–12

144.

Nationale Versorgungsleitlinie (NVL) Chronische KHK (2006) Träger: Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Autoren: Donner-Banzhoff N, Held K, Laufs U et al (Hrsg: ÄZQ) http://www.versorgungsleitlinien.de/themen/khk/pdf/nvl_khk_lang.pdf

145.

Bhatt DL, Steg PG, Ohman EM et al (2006) REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295(2):180–189PubMed

146.

Smith SC Jr, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372PubMed

147.

Gohlke H, Albus C, Bönner G et al (2007) Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. Deutsche Gesellschaft Für Kardiologie − Herz- und Kreislaufforschung e.V

148.

Röther J, Alberts MJ, Touzé E et al (2008) Steg on behalf of the REACH Registry Investigators Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. Cerebrovasc Dis 25:366–374PubMed

149.

Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 14 [Suppl 2]:1–113

150.

Sivenius J, Cunha L, Diener HC et al (1999) Antiplatelet treatment does not reduce the severity of subsequent stroke. European Stroke Prevention Study 2 Working Group. Neurology 53:825–829PubMed

151.

Yilmaz A, Sechtem U (2008) Cardiac imaging in suspected coronary artery disease. Dtsch Med Wochenschr 133:644–649PubMed

Titel: Kardiologische Diagnostik nach zerebraler Ischämie
Konsensuspapier der Arbeitsgemeinschaft Herz und Hirn der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK) und der Deutschen Schlaganfallgesellschaft e.V. (DSG)
verfasst von: Prof. Dr. U. Laufs
U.C. Hoppe
S. Rosenkranz
P. Kirchhof
M. Böhm
H.-C. Diener
M. Endres
M. Grond
W. Hacke
T. Meinertz
E.B. Ringelstein
J. Röther
M. Dichgans
Publikationsdatum: 01.04.2010
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 4/2010
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-009-2901-3

Neu in den Fachgebieten Neurologie und Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Kardiologische Diagnostik nach zerebraler Ischämie

Konsensuspapier der Arbeitsgemeinschaft Herz und Hirn der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK) und der Deutschen Schlaganfallgesellschaft e.V. (DSG)

Auszug

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Schlaganfall bei Tumorpatienten

Erhaltene Reflexe, Propriozeption, SNAPs: trotzdem Friedreich-Ataxie

Welche Faktoren beeinflussen die Serumkonzentration von Levetiracetam?

HIV-assoziierte Neuropathien

Entmarkungserkrankungen

Anti-NMDA-Rezeptor-Enzephalitis

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen